Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 6/20 | 0.52 |
| ▸ | MMP1 | P03956 | 5/20 | 0.52 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.52 |
| ▸ | MMP3 | P08254 | 4/20 | 0.49 |
| ▸ | MMP8 | P22894 | 3/20 | 0.49 |
| ▸ | MMP7 | P09237 | 2/20 | 0.49 |
| ▸ | MMP12 | P39900 | 2/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | MMP14 | P50281 | 1/20 | 0.46 |
| ▸ | BMP1 | P13497 | 4/20 | 0.46 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.46 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6331632 | 0.85 | TAS2R14 (0.56) | MMP13MMP1TAS2R14MMP3MMP8 | |
| SCHEMBL6323499 | 0.83 | MMP13 (0.52) | MMP13MMP1TAS2R14MMP3MMP8 | |
| SCHEMBL6323932 | 0.82 | TAS2R14 (0.62) | TAS2R14BMP1 | |
| SCHEMBL6323224 | 0.82 | ADAM17 (0.65) | MMP13MMP1MMP3MMP8KEAP1 | |
| SCHEMBL18796806 | 0.81 | MMP13 (0.51) | MMP13MMP1TAS2R14MMP3MMP8 | |
| SCHEMBL7641340 | 0.81 | MMP1 (0.57) | MMP13MMP1TAS2R14MMP3MMP8 | |
| SCHEMBL9287153 | 0.79 | RORC (0.68) | TAS2R14KEAP1BMP1 | |
| SCHEMBL14781073 | 0.79 | MMP1 (0.50) | MMP13MMP1TAS2R14MMP3MMP8 | |
| SCHEMBL598146 | 0.78 | MMP3 (0.79) | MMP13MMP1MMP3MMP8MMP7 | |
| SCHEMBL15772656 | 0.77 | RORC (0.59) | TAS2R14MEP1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014840-A1 | Thiol sulfonamide metalloprotease inhibitors | PHARMACIA CORPORATION | 2005-01-20 | — | — | US | disclosed |
| US-6747027-B1 | SELECTIVELY INHIBITS IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-13 OVER IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-1 | PHARMACIA CORPORATION | 2004-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014840-A1 | Thiol sulfonamide metalloprotease inhibitors | MMP12, MMP13, MMP3 | MMP13 2/4885MMP1 13/4885TAS2R14 1996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.